Information Provided By: 
Fly News Breaks for January 28, 2016
CELG
Jan 28, 2016 | 10:42 EDT
Piper Jaffray analyst Joshua Schimmer said Celgene reported strong Q4 growth and he believes its guidance for 2016 product sales growth and EPS both appear "achievable and surpassable", he tells investors in a post-earnings research note. The analyst, who thinks the company still has one of the highest and most sustainable 5+ year growth outlooks as well as an attractive valuation, keeps an Overweight rating and $163 price target on the stock, which is down 4% to $98 in morning trading.
News For CELG From the Last 2 Days
There are no results for your query CELG
